Alterity Therapeutics has recently announced the the Michael J. Fox Foundation will be funding a dose optimization trial for ATH434. According to BioSpace, this grant is the second from the…
In early February, pharmaceutical company Ellodi Pharmaceuticals ("Ellodi") shared that its drug candidate, APT-1011, received the FDA's Fast Track designation. APT-1011, or fluticasone propionate oral disintegrating tablet, is designed to…
I used to love a margarita on the rocks with a twist. At some point in my late 20s, I went from the carefree life of a young healthy person…
424 words (source) vs. 431 words (mine) - 3% match Earlier this week, Guinea, a country located in West Africa, reported new cases of Ebola, a rare and deadly infection.…
Dr. Oliver Dorigo of the Stanford University Medical Center was the medical source for an article featured in Oncology. Dr. Dorigo explained that if a woman with ovarian cancer has…
By Tom Seaman If you are like me and probably most people, in today’s busy world it is a big challenge to be still and mentally at ease. This is…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Clinical stage pharmaceutical company KalVista Pharmaceuticals ("KalVista") saw positive data from a Phase 2 clinical trial evaluating its experimental therapy KVD900, shared MedCity News. The Phase 2 trial was exploring…
Genethon and WhiteLab Genomics have entered into a partnership agreement, which will allow them to further develop their work in artificial intelligence and gene therapy. Within the terms of the…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
